Search

Search Results

• EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

  Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan

  e2026033

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.033

  306

  PDF: 329

  Suppl. Files: 53

  HTML: 83

• THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis

  Kun Yang, Jian Xiao

  e2024001

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.001

  1459

  PDF: 1455

  PDF: 1036

  HTML: 227

• THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

  Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin

  e2020021

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.021

  2298

  PDF: 1281

  HTML: 402

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2602

  PDF: 752

  HTML: 1641

• Thalidomide treatment for thrombocytopenia secondary to hypersplenism in children with β-thalassemia major: a case series Thalidomide treatment for thrombocytopenia

  Kun Yang

  e2025037

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.037

  936

  PDF: 761

  HTML: 201

• Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

  Alhossain A. Khalafallah, Matthias Maiwald, Amanda Cox, Burns Denise, Gerald Bates, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain

  e2010005

  2010-04-20

  https://doi.org/10.4084/mjhid.2010.005

  1192

  PDF: 582

  HTML: 1186

• EFFECTS OF THALIDOMIDE ON ENDOTHELIAL ACTIVATION AND STRESS INDEX IN CHILDREN WITH Β-THALASSEMIA MAJOR

  Kun Yang

  e2024076

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.076

  1108

  PDF: 616

  HTML: 155

• THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

  Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

  e2010009

  2010-05-03

  https://doi.org/10.4084/mjhid.2010.009

  1596

  PDF: 737

  HTML: 662

• POEMS SYNDROME: AN UPDATE

  Andrea Nozza

  e2017051

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.051

  3419

  PDF: 1687

  HTML: 1768

• LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

  Patrizia Tosi

  e2013037

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.037

  1359

  PDF: 929

  HTML: 1291

  fig 1A: 200

  figure1B: 175

• "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

  Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

  e2010013

  2010-06-01

  https://doi.org/10.4084/mjhid.2010.013

  1492

  PDF: 680

  HTML: 1586

• REAL WORLD MULTIPLE MYELOMA REGISTRY FROM JORDAN, A DEVELOPING COUNTRY.

  Abdalla Awidi, Farah Qasem, A'sem Abu-Qamar, Batool Aqel, Rand Aladayleh, Ilham Alteerah, Ahmad Magableh, , Hisham Bawa”neh, Feras Al-fararjeh

  e2022031

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.031

  1358

  PDF: 777

  HTML: 413

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  2050

  PDF: 1720

  HTML: 315

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5362

  PDF: 1981

  HTML: 1817

• EARLY APPLICATION OF HIGH CUT-OFF HAEMODYALISIS FOR DE-NOVO MYELOMA NEPHROPATHY IS ASSOCIATED WITH LONG-TERM DIALYSIS-INDEPENDENCY AND RENAL RECOVERY

  Alhossain A. Khalafallah, Sie Wuong Loi, Sarah Love, Muhajir B. Mohamed, Rose Mace, Ramy Khalil, Miriam Girgs, Rajesh Raj, Mathew Mathew

  e2013007

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.007

  1410

  PDF: 680

  HTML: 2543

  cover letter: 211

• COMPREHENSIVE REVIEW OF GENETIC AND EPIGENETICS REGULATION OF FETAL HEMOGLOBIN IN β-HEMOGLOBINOPATHIES: FROM MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS HbF Genetics in Anemia

  Yousef Saeed Mohammad Abu Za’ror, Joseph Bagi Suleiman, Fatima Azzahra Delmani, Jehad Farouq Alhmoud, Amer Mohammad Ayasreh, Sarah Ihsan Al-wendawi, Maryam Azlan

  e2026046

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.046

  704

  PDF: 569

  HTML: 74

• FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

  Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni

  e2024066

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.066

  1081

  PDF: 645

  Html: 169

• THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION

  Flavio De Maio, Delia Mercedes Bianco, Giovanni Delogu

  e2022021

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.021

  1345

  PDF: 784

  HTML: 319

• Common variable immunodeficiency due to a novel NFKB1 variant in a child with thalassemia major CVID with thalassemia major

  Kun Yang

  e2023053

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.053

  765

  PDF: 584

  HTML: 188

• VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS

  Anna M. Randi, Mike A Laffan, Richard D. Starke

  e2013060

  2013-09-02

  https://doi.org/10.4084/mjhid.2013.060

  3847

  PDF: 1630

  HTML: 8222

  Randi Fig: 198

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2536

  PDF: 811

  HTML: 1743

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1604

  PDF: 853

  HTML: 207

• Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study

  Mauro Passucci, Francesca Fazio, Jacopo Micozzi, Manhaz Shafii Bafti, Giovanni Manfredi Assanto, Alfonso Piciocchi, Maurizio Martelli, Maria Teresa Petrucci

  e2024041

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.041

  1294

  PDF: 1085

  Suppl. Files: 723

  HTML: 84

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  5972

  PDF: 2389

  HTML: 1530

• IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

  Jean Elcheikh

  e2013026

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.026

  1341

  PDF: 762

  HTML: 1481

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7774

  PDF: 2468

  HTML: 2104

  Table 1.: 237

  Table 2.: 247

  Table 3.: 230

  Table 4.: 223

• Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy

  Gianluca Cavallaro

  e2024049

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.049

  2266

  HTML: 149

  PDF: 1170

• RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

  Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2023062

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.062

  1327

  PDF: 1102

  HTML: 245

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1698

  PDF: 664

  HTML: 2442

• Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

  Jacopo Monticelli, Roberto Luzzati, Cristina Maurel, Chiara Rosin, Romina Valentinotti, Claudio Farina

  e2015011

  2014-12-24

  https://doi.org/10.4084/mjhid.2015.011

  1747

  PDF: 1107

  HTML: 6557

  original file with images: 299

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1652

  PDF: 659

  HTML: 1196

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4442

  PDF: 1792

  HTML: 1120

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  2355

  PDF: 1755

  HTML: 950

• Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

  Alessandro Gozzetti, Vania Rossi, Alfonso Cerase, Giulia Papini, Marzia Defina, Monica Bocchia

  e2012041

  2012-06-19

  https://doi.org/10.4084/mjhid.2012.041

  1151

  PDF: 768

  HTML: 761

• Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

  Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà, Maria Teresa Petrucci

  e2012035

  2012-05-07

  https://doi.org/10.4084/mjhid.2012.035

  1610

  PDF: 777

  HTML: 660

• A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

  Mauro Passucci, Francesca Fazio, Maria Teresa Petrucci

  e2023012

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.012

  1048

  PDF: 979

  HTML: 419

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1619

  PDF: 1421

  HTML: 144

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1441

  PDF: 894

  HTML: 231

• Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience

  Edoardo Olivari

  e2025040

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.040

  1092

  PDF: 796

  HTML: 196

• QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

  Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods

  e2011057

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.057

  1442

  PDF: 712

  HTML: 1384

  cover letter: 222

• Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma

  Vincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, Chiara Carrara, Monica Bocchia, Alessandro Gozzetti

  e2025051

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.051

  783

  PDF: 607

  HTML: 49

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1502

  PDF: 1283

  HTML: 330

• PROGNOSTIC IMPACT OF NEUROPILIN-1 EXPRESSION IN EGYPTIAN CHILDREN WITH B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA

  adel abd elhaleim hagag, Nahla A Nosair

  e2015009

  2014-12-28

  https://doi.org/10.4084/mjhid.2015.009

  1684

  PDF: 850

  HTML: 2158

• Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia

  xiaolin yin, Jingting Luo

  e2023050

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.050

  817

  PDF: 578

  HTML: 203

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1232

  PDF: 985

  HTML: 224

• EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

  Pietro Tralongo, Arianna Bakacs, Luigi Maria Larocca

  e2024042

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.042

  4544

  PDF: 1759

  HTML: 1172

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2897

  PDF: 1043

  HTML: 5631

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  2122

  PDF: 873

  HTML: 356

• Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio

  Dr. Enrica A. Martino, Dr. G. Mele, Dr. F. Morabito, Dr. M. Gentile, Dr. E. Vigna

  e2025006

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.006

  2250

  PDF: 1648

  HTML: 450

• Skin Involvement in Primary Systemic Amyloidosis

  susheel kumar

  e2013005

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.005

  1704

  PDF: 915

  HTML: 4413

  Figure 1. Photographs showing (a) enlarged tongue with (b) teeth marks over the lateral margin and (c, d) multiple, papular lesions over lower chest wall: 194

  Figure 2. Microphotograph showing pink eosinophilic homogenous material in the dermis, H&E X 20: 173

  Figure 3. Pink eosinophilic material showing pale orange positivity with Congo red stain: 196